Search Results

You are looking at 11 - 20 of 44 items for :

  • "nephrectomy" x
  • User-accessible content x
Clear All
Full access

Ralph Hauke

Vasey P Aitchison M . Management of renal masses in patients medically unsuitable for nephrectomy— natural history, complications, and outcome . Urology 2004 ; 64 : 909 – 913 . 33. Ozono S Miyao N Igarashi T . Tumour doubling time of

Full access

Mark D. Tyson and Sam S. Chang

The incidence of renal cell carcinoma (RCC) has been steadily increasing for decades. 1 The mainstay of treatment for clinically localized disease is radical nephrectomy and, when technically feasible, partial nephrectomy. Yet, up to 20% to 30

Full access

less, serum LDH level greater than 1.5 times the upper limit of normal (ULN), hemoglobin level below normal, corrected serum calcium level above the ULN, and time from diagnosis and nephrectomy to therapy of less than 1 year.” These NCCN Guidelines

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Sam Bhayani, William P. Bro, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Mayer Fishman, Thomas H. Gallagher, John L. Gore, Steven L. Hancock, Michael R. Harrison, Won Kim, Christos Kyriakopoulos, Chad LaGrange, Elaine T. Lam, Clayton Lau, M. Dror Michaelson, Thomas Olencki, Phillip M. Pierorazio, Elizabeth R. Plimack, Bruce G. Redman, Brian Shuch, Brad Somer, Guru Sonpavde, Jeffrey Sosman, Mary Dwyer and Rashmi Kumar

remains to be determined. Currently, PET alone is not a tool that is standardly used to diagnose kidney cancer or follow for evidence of relapse after nephrectomy. 28 The use of current TNM classification 29 and classification of histologic subtypes 30

Full access

Eric Jonasch

is partial or radical nephrectomy or, in select patients, active surveillance. Further treatment is typically not recommended. “Following nephrectomy, adjuvant therapy for RCC has been an exercise in frustration,” he pointed out. Recent studies

Full access

Benigno Emmanuel Rodriguez Soto, Lorena López Zepeda, Daniela Vázquez Juarez, Alejandro Noguez Ramos, Alberto Villalobos Prieto, Samuel Rivera Rivera, Guillermo Manuel Olivares Beltrán and Raquel Gerson Cwilich

, having 5 patients (35.7%) with favorable risk, intermediate 7 (50%) and poor 2 (14.3%). Nephrectomy was performed in 13 patients (92.9%). At the end of the study, 8 patients have progressed (51.6%), the median PFS reported in the whole group was 3 months

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer and Rashmi Kumar

category 2B (see KID-B, 1–4 of 4; pages 154–157). Additionally, the NCCN Guidelines include follow-up for the first 5 years after nephrectomy, with follow-up evaluation to be extended beyond 5 years at the discretion of the physician. Results from a

Full access

Matthew P. Banegas, Linda C. Harlan, Bhupinder Mann and K. Robin Yabroff

-directed surgery (eg, radical nephrectomy, complete/total/simple nephrectomy, partial/subtotal nephrectomy, or kidney resection with other organ resection) before systemic treatment, among patients who received systemic therapy, was categorized into a binary

Full access

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020

Featured Updates to the NCCN Guidelines

Robert J. Motzer, Eric Jonasch, M. Dror Michaelson, Lakshminarayanan Nandagopal, John L. Gore, Saby George, Ajjai Alva, Naomi Haas, Michael R. Harrison, Elizabeth R. Plimack, Jeffrey Sosman, Neeraj Agarwal, Sam Bhayani, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Thomas H. Gallagher, Steven L. Hancock, Christos Kyriakopoulos, Chad LaGrange, Elaine T. Lam, Clayton Lau, Bryan Lewis, Brandon Manley, Brittany McCreery, Andrew McDonald, Amir Mortazavi, Phillip M. Pierorazio, Lee Ponsky, Bruce G. Redman, Bradley Somer, Geoffrey Wile, Mary A. Dwyer, CGC, Lydia J. Hammond and Griselda Zuccarino-Catania

with stage IV disease who have any poor-risk features, clear cell histology, and high-volume distant metastases, instead of cytoreductive nephrectomy followed by systemic treatment (see KID-2 , page 1281). This recommendation is based on results of the

Full access

Philip J. Saylor and M. Dror Michaelson

://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf . Accessed April 23, 2009 . 11 Flanigan RC Mickisch G Sylvester R . Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis . J Urol 2004 ; 171 : 1071 – 1076 . 12 Flanigan RC Salmon SE Blumenstein BA